Trio exome sequencing as the stand-alone first-tier testing for prenatal diagnosis

Abstract

BACKGROUNDWhole exome sequencing (WES) is increasingly utilized in prenatal diagnosis of fetus with structural abnormality. However, evidence supporting its use as a first-tier genetic test for all pregnancies referred for invasive prenatal procedures remains limited. METHODSWe conducted a multi-center prospective study enrolling 1,382 pregnancies from seven prenatal diagnosis centers all around China. Participants were divided into two groups based on clinical indications: those for whom CMA testing was traditionally recommended (CMA group) and those for whom CMA and WES were sequentially or concurrently recommended (CTW group) according to their indications. After excluding 200 pregnancies terminated prior to genetic test reporting, the cohort included 1,182 cases undergoing independent trio-WES and CMA testing. The primary outcome was determined through follow-up of at least 3 months after delivery. RESULTSTrio-WES yielded an overall diagnostic yield of 17.22%, with an incremental yield of 7.38% for SNVs/Indels not detected by CMA. Even for subjects in the CMA group, theres a diagnostic yield of 4.02%, arising from SNVs/Indels that would be missed by CMA. Trio-WES showed a 100% concordance with CMA on detection of reportable cytogenomic events, with unique advantages over CMA in 6 cases with UPD and 3 cases with exon-level deletion. Importantly, WES results, whether positive, negative or uncertain, significantly impact clinical decision-making for pregnancy. CONCLUSIONSOur findings support the use of prenatal trio-WES as a stand-alone first-tier genetic test for all pregnancies referred for invasive prenatal diagnosis, regardless of indication.